NRL Capital Bets on China-licensed Botulinum Toxin Asset
14 Jan 2026
US$ 20.00
NRL Capital has led the series A funding round of the US-based biotech company Revelyx Bio Inc (Revelyx) for an ......
Tag
Healthcare
Related Publications
A year after Australia’s largest industrial property group, Goodman Group Ltd, partnered with a marquee list of ......
Siguler Guff Advisers LLC has closed its Siguler Guff Global Emerging Markets Growth Opportunity Fund II LP ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.